Novavax inks $1.6B Warp Speed deal to fund COVID vaccine's phase 3 testing, manufacturing Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supply Fauci says U.S. 'still knee-deep in the first wave' of COVID-19 as daily cases top 50K Moderna delay a snapshot of 'squabbles' with U.S. scientists over COVID-19 vaccine trials: Reuters Mayo Clinic CEO blasts 'just-in-time' ordering as pandemic changes supply chain EU in 'constructive' talks with Gilead to nab remdesivir amid U.S. supply grab: report GlaxoSmithKline pens COVID-19 vaccine pact with Medicago Healthcare roundup: Alabama hospital suspends some surgeries as cases spike Biopharma roundup: J&J updates Catalent pact for Italian shot finishing; LabCorp launches at-home test collection service Verma: COVID-19 proving the need for greater interoperability CMS proposes Medicare payment updates to increase use of home dialysis Pharma's pandemic response could help attract tech talent, Novartis digital chief says Featured Story | By Eric Sagonowsky Novavax and its COVID-19 shot are racing against well-funded global pharmaceutical players, but a new deal with the U.S. government will push the biotech's fundraising haul past $2 billion. Under the deal, the biotech will start producing 100 million doses of its later this year. read more |
| |
|---|
|
| | [Webinar] Zero Deviation Mindset: Achieving Agility in Cell Therapy Supply Chains Tuesday, July 21 | 10am ET / 7am PT Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States. Register Now. |
Top Stories By Kyle Blankenship Among the drugmakers seeking an answer for COVID-19, Regeneron once showed promise in its quest to repurpose an older therapy as a treatment and develop a novel antibody cocktail. Now, thanks to disappointing data, that first path appears blocked—but Regeneron will sport a major U.S. investment for its antibody hopeful. read more By Robert King Infectious disease expert Anthony Fauci cautioned the U.S. is not seeing the start of a second wave of novel coronavirus because the first wave has still not ended. read more By Amirah Al Idrus Late last week, Stat reported that Moderna would delay the phase 3 study of its COVID-19 vaccine, thanks to changes to the trial’s protocols. Such changes are not uncommon, highlighting just how closely watched anti-COVID-19 efforts are, but the delay is part of a trend of tensions in the biotech’s relationship with the U.S. government. read more By Robert King The head of Mayo Clinic said the COVID-19 pandemic will change how the system approaches supply chain management. read more By Angus Liu After the Trump administration locked up almost all doses of Gilead Sciences’ COVID-19 treatment remdesivir for the next few months, Europe decided it needs to look out for itself, too. The EU health commissioner reportedly spoke with Gilead execs Monday to iron out a supply deal. read more By Ben Adams Hoping to broaden shots on target, GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Johnson & Johnson updated its pact with Catalent to secure shot finishing at the CDMO's Italian site. CureVac nabbed $85 million from the EU to scale its mRNA vaccine production. LabCorp launched a new COVID-19 test collection service, and President Donald Trump is touting hydroxychloroquine—again. read more By Paige Minemyer Centers for Medicare & Medicaid Services Administrator Seema Verma said the COVID-19 pandemic has “exposed a lot of inefficiencies” in the healthcare system—with one of the largest being data sharing and access. read more By Paige Minemyer The Trump administration has proposed an enhanced Medicare add-on payment to encourage greater use of home dialysis for beneficiaries with end-stage renal disease. read more By Beth Snyder Bulik The COVID-19 pandemic changed consumer perceptions of the pharma industry, but it changed some professionals' minds, too. Almost three-fourths (73% ) of tech professionals say their opinion of the industry has improved during the pandemic, thanks to its response in the search for treatments and vaccines, according to a new Novartis study. read more | 